Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nanobiotix SA - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NBTX
Nasdaq
8731
https://www.nanobiotix.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nanobiotix SA - ADR
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
- Apr 24th, 2024 8:40 pm
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
- Apr 17th, 2024 8:15 pm
11 Best Nanotechnology Stocks To Invest In
- Apr 13th, 2024 2:02 pm
Voting Rights and Shares Capital of the Company
- Apr 10th, 2024 8:15 pm
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
- Apr 2nd, 2024 8:15 pm
Nanobiotix to Present at Upcoming Investor Conferences in March
- Mar 6th, 2024 9:15 pm
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
- Jan 31st, 2024 9:15 pm
Baillie Gifford Bolsters Stake in Nanobiotix SA
- Jan 30th, 2024 4:02 pm
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
- Jan 29th, 2024 9:15 pm
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
- Dec 26th, 2023 7:00 am
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
- Dec 4th, 2023 9:22 pm
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
- Nov 13th, 2023 9:15 pm
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
- Nov 9th, 2023 9:15 pm
NANOBIOTIX Announces Closing of Global Offering
- Nov 7th, 2023 9:01 pm
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
- Nov 6th, 2023 7:00 am
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
- Nov 2nd, 2023 2:49 pm
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
- Nov 1st, 2023 10:32 pm
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
- Oct 23rd, 2023 6:00 am
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months
- Oct 4th, 2023 8:30 pm
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
- Sep 29th, 2023 8:15 pm
Scroll